| Code | CSB-RA011587MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Ustekinumab-ttwe, designed to target IL12B, the p40 subunit shared by both interleukin-12 (IL-12) and interleukin-23 (IL-23). IL12B encodes a critical component of these pro-inflammatory cytokines that play essential roles in T-helper cell differentiation and immune responses. IL-12 promotes Th1 cell development and IFN-γ production, while IL-23 is crucial for Th17 cell maintenance and function. Dysregulation of IL12B-containing cytokines is implicated in various autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and inflammatory bowel disease.
Ustekinumab-ttwe is an FDA-approved therapeutic antibody that neutralizes both IL-12 and IL-23 by binding to their shared p40 subunit, preventing receptor engagement and downstream signaling. This biosimilar antibody provides researchers with a valuable tool for investigating IL-12/IL-23 pathways, studying cytokine-mediated immune responses, and exploring mechanisms underlying chronic inflammatory diseases. It serves as an important reagent for immunological research and therapeutic mechanism studies.
There are currently no reviews for this product.